Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.47, sa.2, ss.554-562, 2017 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 47 Sayı: 2
- Basım Tarihi: 2017
- Doi Numarası: 10.3906/sag-1602-77
- Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.554-562
- Anahtar Kelimeler: Xenobiotic/drug metabolizing enzymes, TP53, polymorphisms, response to chemotherapy, survival, nonsmall cell lung cancer, GERM-LINE POLYMORPHISMS, GENETIC POLYMORPHISMS, P53 GENE, CODON-72 POLYMORPHISM, TRANSFERASE GENES, CIGARETTE-SMOKING, 2E1 POLYMORPHISM, MDM2 SNP309, ASSOCIATION, RISK
- Ankara Üniversitesi Adresli: Evet
Özet
Background/aim: The association between polymorphisms of xenobiotic/drug metabolizing enzymes and TP53 and response to chemotherapy and survival of patients with nonsmall cell lung cancer (NSCLC) are limited and inconclusive. In this study, CYP2E1*5B, CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and survival in 137 advanced stage NSCLC patients were investigated.